Skip to main content
. Author manuscript; available in PMC: 2018 Dec 2.
Published in final edited form as: Salud Publica Mex. 2018 Jul-Aug;60(4):423–431. doi: 10.21149/9193

Table 3:

Exclusive trial of tobacco, exclusive trial of e-cigarette and trial of both among never smokers at baseline in Argentinaa and Mexicob

Trial of regular tobacco only Trial of E-cigarette only Trial of both
Prevalence OR AOR Prevalence OR AOR Prevalence OR AOR
ARGENTINA n=344 (20.5%) n=41 (2.4%) n=61 (3.7%)
Non susceptible 14.7% 1 1 2.6% 1 1 3.0% 1 1
Smoking Susceptibility 38.5% 3.62*** (2.80–4.68) 2.85*** (2.15–3.77) 2.0% 0.85 (0.38 – 1.88) 0.39 (0.13 – 1.14) 5.7% 1.86* (1.05 – 3.28) 1.50 (0.82 – 2.76)
MEXICO n=559 (11.5%) n=467 (9.6%) n=632 (13.0%)
Non susceptible 9.8% 1 1 8.9% 1 1 10.2% 1 1
Smoking Susceptibility 17.3% 1.91*** (1.58–2.32) 1.61*** (1.31–1.98) 12.1% 1.43** (1.15 – 1.77) 1.29* (1.02–1.63) 22.6% 2.57*** (2.14–3.08) 1.97*** (1.62 – 2.39)
*

p<0.05;

**

p<0.01;

***

p<0.001

The model was adjusted by age, sex, type of school, parental education, sensation seeking index, poor school performance, parenting style, network exposure to tobacco and POS exposure.

a

Surveys in Buenos Aires, Cordoba and Tucuman. October- November, 2015

b

Survey in Mexico City, Guadalajara, and Monterrey. October- November 2016.